Back to Team
Nedim Can Çevik

Nedim Can Çevik, MSc, PhD Cand.

Co-Founder & Scientific Strategy & Program Coordination Lead

Leads scientific strategy and cross-project coordination across translational research, molecular biotechnology, biomarker discovery and experimental model development.

Current Roles

  • European Association for Cancer Research (EACR) — Ambassador
  • Istanbul Kent University — R&D Specialist, CellKent Director (2026)
  • Imperion Research and Biotechnology — Co-founder & Research Lead (2025 – present)
  • Bilim İlaç — R&D Advisor
  • Hekim İlaç — Scientific Board Member
  • Memorial Hospital — HCC, Colorectal, PDAC; Scientific Board Member
  • Bloocell — R&D Advisor
  • Acıbadem Tekmer — R&D Advisor
  • Atabay — NDA Signed

Previous Roles

  • Acıbadem Pancreatic Cancer Research Center — Co-founder, R&D Lead (2018–2026)
  • Genobio — Project Lead (2023–2025)
  • Biota — R&D Advisor (2021–2023)
  • Labcell — Junior Researcher (2016/2017)

Key Achievements

  • Secured 6 TÜBİTAK grants and 2 European grants
  • Biotechnology pipeline: LNA-based colorectal cancer kit & recombinant protein production
  • Co-founded PANKAM; managing 5 translational pancreatic projects
  • 4 peer-reviewed manuscripts in pipeline; 24-month collaboration at TU Munich

Education

  • PhD Biotechnology, Yeditepe Univ., 2025–
  • MSc Medical Biotechnology, Acıbadem Univ., 2022
  • BSc Genetics & Bioengineering, Yeditepe Univ., 2016

Core Skills

Cell & Gene Tech

Primary/3-D cultures, neuronal-cancer cell culture handling, DRG & stellate isolation, bone marrow derived hematopoietic stem cell isolation-differentiation to M0/M1/M2 macrophages, CRISPR/siRNA/shRNA, ICC, 3D ECM embedded migration (live cell microscopy), colony forming, scratch assay, monoclonal antibody production via hybridoma, insert based co-culture assay, annexin V, Comet, CCK8 toxicity assay.

In-Vivo Models

Animal handling, transgenic & caerulein induced acute & chronic pancreatitis models, transgenic & orthotopic tumors, monoclonal antibody production via hybridoma technique with mice, pain assays (Von-Frey), cognitive assays, microsurgery (Open-Field, Morris-Maze), genotyping.

Analytics

WB, ELISA, PCR (common, gradient, inverted, touch-down), qPCR, gel electrophoresis, tissue preservation, FACS, microtome, H&E, IHC, IF, digital histopathology (QuPath, ImageJ, GraphPad Prism, BioRender, MATLAB, C++, AutoCAD, Mathematica).

Awards & Presentations

  • 2023 EPC Meeting — Poster Presentation
  • 2024 HPB Congress — Poster Presentation & Travel Grant
  • 2024 EPC Meeting — Poster Presentation & Travel Grant
  • 2024 IHPBA Congress — Poster Presentation & Travel Grant
  • 2025 EPC Meeting — Oral Lecture
  • 2025 EACR Conference Cancer Neuroscience — Poster Presentation & Travel Grant
  • 2025 Izmir Institute of Technology — Invited Speaker
  • 2025 Istanbul Kent University — Invited Speaker
  • 2026 GeneXplore ITU — Invited Speaker
  • 2026 Istanbul Atlas University — Invited Speaker
  • 2026 International IV. GENESIS Symposium, Haliç University — Workshop
  • EPC/IAP Joint Meeting 2026 — Oral Presentation & Best Abstract
  • Pancreatic Cancer Conference 2026 — Poster Presentation & Flash Talk

Key Articles

  • Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses

    Cancer Cell · IF 44.5

  • Dynamics and cytokinic regulation of immune cell infiltration in genetically engineered mouse models of pancreatic cancer dictate the sensitivity to immunotherapy

    Cancer Communications · IF 24.9

  • Targeting the undruggable oncogenic KRAS: the dawn of hope

    JCI Insight · IF 6.1

  • Mechanisms of T-Cell Exhaustion in Pancreatic Cancer

    Cancers · IF 4.4

  • Targeting NMDA Receptor 1A Ameliorates Pain in Mice with Chronic Pancreatitis (Abstract)

    Pancreatology · IF 3.8